The Health Ministry’s National Pharmaceutical Regulatory Agency (NPRA) has received the clinical data on the Covid-19 vaccine from Pfizer-BioNTech, says Khairy Jamaluddin.
The Science, Technology and Innovations Minister said the decision to use the vaccine from the company lies with NPRA and the Health Ministry upon the completion of the registration and approval process.
“The process has begun and all data that has been supplied by Pfizer-BioNTech will be looked into by NPRA.
“The supply of Covid-19 vaccines from Pfizer-BioNTech is expected to be received in the first quarter of next year comprising 12.8 million dosages to help immunise 20% or 6.4 million Malaysians, ” said Khairy in reply to Lim Guan Eng (PH-Bagan) during Ministerial Question Time.
Lim had asked why the Pfizer-BioNTech vaccine was chosen above other vaccines.
Khairy said the government inked the deal with Pfizer-BioNTech on Nov 24 based on interim clinical reports published in The New England Journal of Medicine, which showed the vaccine had a 95% efficacy rate.
The government had also gained data access to look into the quality, safety and efficacy of the vaccine, he said.
“The vaccine has also received Emergency Use Authorisation from seven countries – the United Kingdom, the United States, Bahrain, Canada, Saudi Arabia, Mexico and Singapore, ” said Khairy, who added that the Special Committee on Covid-19 Vaccine Supply Access Guarantee was also considering other candidates that were in phase three of clinical trials for Malaysia’s use.